710 related articles for article (PubMed ID: 35562141)
1. Liquid biopsy in CNS tumors: Current status & future perspectives.
Husain N; Husain A; Mishra S; Srivastava P
Indian J Pathol Microbiol; 2022 May; 65(Supplement):S111-S121. PubMed ID: 35562141
[TBL] [Abstract][Full Text] [Related]
2. The Utility of Liquid Biopsy in Central Nervous System Malignancies.
Nevel KS; Wilcox JA; Robell LJ; Umemura Y
Curr Oncol Rep; 2018 Jun; 20(8):60. PubMed ID: 29876874
[TBL] [Abstract][Full Text] [Related]
3. Liquid Biomarkers for Improved Diagnosis and Classification of CNS Tumors.
Bunda S; Zuccato JA; Voisin MR; Wang JZ; Nassiri F; Patil V; Mansouri S; Zadeh G
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925295
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsy: current technology and clinical applications.
Nikanjam M; Kato S; Kurzrock R
J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847
[TBL] [Abstract][Full Text] [Related]
5. Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications.
Boire A; Brandsma D; Brastianos PK; Le Rhun E; Ahluwalia M; Junck L; Glantz M; Groves MD; Lee EQ; Lin N; Raizer J; Rudà R; Weller M; Van den Bent MJ; Vogelbaum MA; Chang S; Wen PY; Soffietti R
Neuro Oncol; 2019 May; 21(5):571-584. PubMed ID: 30668804
[TBL] [Abstract][Full Text] [Related]
6. Liquid biopsy and their application progress in head and neck cancer: focus on biomarkers CTCs, cfDNA, ctDNA and EVs.
Meng Y; Bian L; Zhang M; Bo F; Lu X; Li D
Biomark Med; 2020 Oct; 14(14):1393-1404. PubMed ID: 33073579
[TBL] [Abstract][Full Text] [Related]
7. The potential of liquid biopsy in the management of cancer patients.
Markou A; Tzanikou E; Lianidou E
Semin Cancer Biol; 2022 Sep; 84():69-79. PubMed ID: 35331850
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid circulating tumour DNA as a liquid biopsy for central nervous system malignancies.
Escudero L; Martínez-Ricarte F; Seoane J
Curr Opin Neurol; 2020 Dec; 33(6):736-741. PubMed ID: 33177377
[TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy for precision diagnostics and therapeutics.
Anitha K; Posinasetty B; Naveen Kumari K; Chenchula S; Padmavathi R; Prakash S; Radhika C
Clin Chim Acta; 2024 Feb; 554():117746. PubMed ID: 38151071
[TBL] [Abstract][Full Text] [Related]
10. Liquid biopsy in breast cancer: A comprehensive review.
Alimirzaie S; Bagherzadeh M; Akbari MR
Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
[TBL] [Abstract][Full Text] [Related]
11. Detection of tumor-derived cell-free DNA in cerebrospinal fluid using a clinically validated targeted sequencing panel for pediatric brain tumors.
Ronsley R; Karvonen KA; Cole B; Paulson V; Stevens J; Crotty EE; Hauptman J; Lee A; Stasi SM; Lockwood CM; Leary SES
J Neurooncol; 2024 Jun; 168(2):215-224. PubMed ID: 38755519
[TBL] [Abstract][Full Text] [Related]
12. Novel Molecular Markers in Glioblastoma-Benefits of Liquid Biopsy.
Birkó Z; Nagy B; Klekner Á; Virga J
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053907
[No Abstract] [Full Text] [Related]
13. The Role of Liquid Biopsies in Pediatric Brain Tumors.
Tang K; Gardner S; Snuderl M
J Neuropathol Exp Neurol; 2020 Sep; 79(9):934-940. PubMed ID: 32766689
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA profiling for childhood brain tumors: Technical challenges and evidence for utility.
Liu AP; Northcott PA; Robinson GW; Gajjar A
Lab Invest; 2022 Feb; 102(2):134-142. PubMed ID: 34934181
[TBL] [Abstract][Full Text] [Related]
15. Current Role and Future Potential of CSF ctDNA for the Diagnosis and Clinical Management of Pediatric Central Nervous System Tumors.
Miller AM; Karajannis MA
J Natl Compr Canc Netw; 2022 Dec; 20(12):1363-1369. PubMed ID: 36509077
[TBL] [Abstract][Full Text] [Related]
16. Cell Free DNA as an Evolving Liquid Biopsy Biomarker for Initial Diagnosis and Therapeutic Nursing in Cancer- An Evolving Aspect in Medical Biotechnology.
Ray SK; Mukherjee S
Curr Pharm Biotechnol; 2022; 23(1):112-122. PubMed ID: 33308128
[TBL] [Abstract][Full Text] [Related]
17. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
[TBL] [Abstract][Full Text] [Related]
19. Liquid biopsy: possibilities and limitations in uro-oncology.
López-Guerrero JA; Pastor-Navarro B; Claramunt-Alonso R; García-Flores M; Rubio-Briones J
Arch Esp Urol; 2022 Mar; 75(2):203-214. PubMed ID: 35332890
[TBL] [Abstract][Full Text] [Related]
20. The Different Facets of Liquid Biopsy: A Kaleidoscopic View.
Eslami-S Z; Cortés-Hernández LE; Cayrefourcq L; Alix-Panabières C
Cold Spring Harb Perspect Med; 2020 Jun; 10(6):. PubMed ID: 31548226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
